Barrett's-Associated Neoplasia, Cytology
Barrett’s esophagus (BE) is a premalignant condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by columnar epithelium, most often as a consequence of chronic gastroesophageal reflux disease (GERD). It predominantly affects middle-aged to older adults and is more common in males, individuals with central obesity, tobacco use, and chronic GERD. BE is clinically significant because it represents the principal precursor lesion to esophageal adenocarcinoma (EAC), an aggressive malignancy with rising incidence and poor prognosis when diagnosed at advanced stages.
The diagnosis of BE is established endoscopically and confirmed histologically by the presence of intestinal metaplasia with goblet cells, although diagnostic criteria may vary among guidelines. Dysplasia is the strongest histologic predictor of progression to carcinoma but is subject to sampling limitations and interobserver variability, particularly in cases classified as indefinite for dysplasia or low-grade dysplasia.
Barrett’s-associated neoplasia follows a stepwise progression from metaplasia to low-grade dysplasia, high-grade dysplasia, and invasive adenocarcinoma. Early identification of dysplastic or neoplastic changes is critical, as endoscopic eradication therapies are effective in preventing progression when disease is detected at an early stage.
Cytologic evaluation of esophageal samples, typically obtained by endoscopic brushings, provides a minimally invasive adjunct to histologic biopsy. Cytology allows assessment of cellular atypia, nuclear abnormalities, architectural disorganization, and features suggestive of dysplasia or malignancy. Liquid-based cytology preparations improve specimen adequacy and cellular preservation and may be combined with ancillary studies when indicated. Cytology is particularly useful when biopsy material is limited, when histologic findings are equivocal, or as part of surveillance strategies aimed at identifying patients who require closer endoscopic follow-up.
- Adjunctive tool for detection of dysplasia or neoplasia in patients with Barrett’s esophagus
- Assists in early identification of Barrett’s-associated adenocarcinoma in high-risk patients
- Useful when histologic biopsy results are indeterminate or limited by sampling
- Supports surveillance and triage decisions, including need for repeat endoscopy or targeted biopsy
Negative for dysplasia or malignant cells
Esophageal cytology brushings
Samples should be placed in appropriate cytology fixative or transport medium and submitted promptly to the laboratory.
Stability
Room temperature: stable in fixative according to manufacturer specifications
Frozen samples: not acceptable
- Dis Esophagus. 2016 Aug;29(6):513-9. [PMID: 26043762]
- Diagnostics (Basel). 2023 Jan 16;13(2):321. [PMID: 36673131]
- Diagn Cytopathol. 2007 Oct;35(10):621-34. [PMID: 17854077]
- Dig Dis Sci. 2017 May;62(5):1216-1222. [PMID: 28265829]
- Am J Surg Pathol. 2016 May;40(5):e45-66. [PMID: 26813745]
- Fam Cancer. 2022 Jan;21(1):115-120. [PMID: 33694069]